BiotechTube
Metagenomi

Metagenomi

MGXPre-clinical
Emeryville, United Statesmetagenomi.co

Metagenomi is pioneering a new era of genetic medicine by harnessing the vast diversity of microbial life through metagenomics to discover and engineer next-generation genome editing tools. Founded by pioneers in the field, the company has built an industry-leading database, identified over 20,000 editing systems, and is advancing a pipeline of in vivo therapies for genetic diseases. With a strong leadership team, strategic partnerships, and a public listing, Metagenomi is positioned to expand its therapeutic reach and translate its novel platform into transformative patient cures.

Market Cap
$53.4M
Pipeline
—
Patents
—
Publications
—

AI Company Overview

Metagenomi is pioneering a new era of genetic medicine by harnessing the vast diversity of microbial life through metagenomics to discover and engineer next-generation genome editing tools. Founded by pioneers in the field, the company has built an industry-leading database, identified over 20,000 editing systems, and is advancing a pipeline of in vivo therapies for genetic diseases. With a strong leadership team, strategic partnerships, and a public listing, Metagenomi is positioned to expand its therapeutic reach and translate its novel platform into transformative patient cures.

Genetic DiseasesCardiometabolic DiseasesCentral Nervous System (CNS) Disorders

Technology Platform

A proprietary metagenomics platform that discovers novel genome editing systems (nucleases, base editors, CAST systems) from environmental microbial DNA, combined with AI-driven screening and modular engineering to develop next-generation in vivo genetic medicines.

Opportunities

Metagenomi's primary growth opportunity lies in leveraging its vast library of discovered editing systems to build a broad pipeline of best-in-class in vivo therapies across multiple disease areas.
Forming additional strategic partnerships with large biopharma companies can provide non-dilutive funding, validate the platform, and accelerate development.
The technology also has potential applications beyond human therapeutics, including agricultural and industrial biotechnology.

Risk Factors

Key risks include the inherent scientific challenges of developing novel, complex in vivo gene editing therapies, such as ensuring safety, specificity, and effective delivery.
The company faces intense competition from established gene editing firms and must successfully navigate a complex intellectual property landscape.
As a pre-revenue public company, it is also exposed to financial market volatility and will require significant capital to fund clinical development.

Competitive Landscape

Metagenomi competes with public gene editing leaders like CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine, who have a clinical head start. Its key differentiation is its metagenomics discovery engine, which accesses a novel and vast reservoir of microbial diversity to potentially find editors with superior properties (size, specificity, function) compared to optimized versions of known systems. Success depends on proving these novel tools offer clear clinical advantages.